Thursday, February 12, 2009

Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA

Feb 12, 2009 - Teva Pharmaceutical Industries Ltd. and Active Biotech today announced that oral laquinimod, an investigational treatment for relapsing-remitting multiple sclerosis (RRMS), has received a Fast Track designation from the U.S. FDA.

The details can be read here.

No comments: